According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for ...

This integrative peptide, derived from a protein in the ... which is our main focus here at Tampa Bay Total Wellness! Tesamorelin is in a class of medications called human growth hormone-releasing ...

MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage ...

Tesamorelin for injection is the only treatment approved in the U.S. to reduce excess abdominal fat in adults with HIV and lipodystrophy. Tesamorelin for injection is approved in the U.S. for the ...

The Company will commercialize the new formulation under the tradename EGRIFTA WR™. Tesamorelin for injection is the only medication approved in the U.S. for the reduction of excess abdominal ...

(RTTNews) - Theratechnologies (TH.TO, THTX) announced the FDA has approved the company's Prior Approval Supplement to the supplemental biologics license application for EGRIFTA SV, or tesamorelin ...